In vivo development of heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA), GISA and daptomycin resistance in a patient with meticillin-resistant S. aureus endocarditis
We report a patient who developed a meticillin-resistant Staphylococcus aureus (MRSA) central venous catheter infection complicated by infective endocarditis. The patient was initially treated with glycopeptides, which led to the development of heterogeneous glycopeptide resistance, the detection of which required the use of a macro Etest screening test. Subsequently, the causative strain, confirmed by PFGE as a UK epidemic MRSA-15, was treated with daptomycin, and again resistance developed in vivo. The development in vivo of resistance to both these agents suggests that the resistance mechanisms may be associated. We suggest that the clinician managing MRSA infection should anticipate daptomycin resistance when reduced glycopeptide susceptibility is detected.
HaydenM. K.,
RezaiK.,
HayesR. A.,
LolansK.,
QuinnJ. P.,
WeinsteinR. A.2005; Development of daptomycin resistance in vivo in methicillin resistant Staphylococcus aureus
. J Clin Microbiol 43:5285–5287[CrossRef]
JonesT.,
YeamanM. R.,
SakoulasG.,
YangS. J.,
ProctorR. A.2008; Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry and drug binding. Antimicrob Agents Chemother 52:269–278[CrossRef]
MurchanS.,
KaufmannM. E.,
DeplanoA.,
de RyckR.,
StruelensM.,
ZinnC. E.,
FussingV.,
SalmenlinnaS.,
Vuopio-VarkilaJ.other authors2003; Harmonization of pulsed-field gel electrophoresis protocols for epidemiological typing of strains of methicillin-resistant Staphylococcus aureus : a single approach developed by consensus in 10 European laboratories and its application for tracing the spread of related strains. J Clin Microbiol 41:1574–1585[CrossRef]
NeohH. M.,
CuiL.,
YuzawaH.,
TakeuchiF.,
MatsuoM.,
HiramatsuK.2008; Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. Antimicrob Agents Chemother 52:45–53[CrossRef]
PatelJ. B.,
JevittL. A.,
HagemanJ.,
McDonaldL. C.,
TenoverF. C.2006; An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus
. Clin Infect Dis 42:1652–1653[CrossRef]
SharmaM.,
RiedererK.,
ChaseP.,
KhatibR.2008; High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteraemia. Eur J Clin Microbiol Infect Dis 27:433–437[CrossRef]
VossA.,
MoutonJ. W.,
van ElzakkerE. P.,
HendrixR. G.,
GoessensW.,
KluytmansJ. A.,
KrabbeP. F.,
de NeelingH. J.,
SloosJ. H.other authors2007; A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA). Ann Clin Microbiol Antimicrob 6:9[CrossRef]
WoottonM.,
HoweR. A.,
HillmanR.,
WalshT. R.,
BennettP. M.,
MacGowanA. P.2001; A modified population analysis profile method to detect Staphylococcus aureus with decreased susceptibilities to vancomycin in a UK hospital. J Antimicrob Chemother 47:399–404[CrossRef]
In vivo development of heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA), GISA and daptomycin resistance in a patient with meticillin-resistant S. aureus endocarditis